Healthcare Industry Insights: February 2019

Tuesday 26 February 2019

Medical Morphine Market is Driven by Increasing Morphine Consumption in the US

27 February 2019, The global Medical Morphine Market is expected to reach USD 13.32 billion by 2024, driven by increasing morphine consumption in the U.S. The increasing prevalence of arthritis and cancer in geriatric patients is projected to impact the morphine market globally positively.

North America dominated the market by contributing more than 75.0% of the share in 2016 and continue to dominate owing to the increasing number of prescriptions for morphine in the U.S. North American market for the same is expected to grow at a CAGR of 2.9% over the forecast period. However, lack of availability of medical morphine in countries such as India is expected to hamper the growth of the market.

In terms of route of administration, the oral segment is expected to grow at the fastest CAGR over the projected period owing to its dose accuracy, high accessibility, and ease of carrying compared to injectables and other counterparts.

On the basis of indication, others segment is expected to grow at the fastest CAGR of 3.1% over the forecast period owing to increasing number of prescriptions of morphine in U.S. for nominal conditions. The cancer segment is expected to exhibit lucrative growth due to increasing prevalence of bone cancer globally.

Browse Details of Report @ https://www.hexaresearch.com/research-report/medical-morphine-market

Morphine with its use in therapeutics is also one of the most abused drug globally. Respective governments are introducing initiatives to prevent substance abuse and decrease death rates caused by morphine.

Furthermore, researchers are concentrating on drug abuse treatment for opioid addicts which is expected to reduce the illicit use of morphine. For instance, in August 2017, researchers at University of California San Diego in collaboration with CARI therapeutics commenced development of a biosensor capable of detecting opioids in human bodies.

Hexa Research has segmented the global medical morphine market based on Route of Administration , Indication and region:

Segmentation by Route of Administration, 2014 - 2024 (USD Million)
• Oral
• Injectables
• Others

Segmentation by Indication, 2014 - 2024 (USD Million)
• Cancer
• Arthritis
• Others

Segmentation by Region, 2014 - 2024 (USD Million)
• North America
• U.S.
• Europe
  • Germany
• Asia Pacific
  • China
  • India
• Rest of the World

Key players analyzed
• Mallinckrodt Pharmaceuticals
• Alcaliber S.A.
• Purdue Pharma L.P.
• Pfizer Inc.
• Johnson Matthey Fine Chemicals
• Sun Pharmaceutical Industries Ltd.
• Verve Health Care Ltd.
• Taj Pharmaceuticals Limited
• NORTHEAST PHARM
• MANUS AKTTEVA BIOPHARMA LLP

Browse Related Category Market Reports @ https://www.hexaresearch.com/research-category/pharmaceuticals-industry

About Us:

Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:

Ryan Shaw

Hexa Research

Felton Office Plaza

6265 Highway 9

Felton, California 95018

United States

Phone: +1-800-489-3075

Email: sales@hexaresearch.com

Website: https://www.hexaresearch.com

Monday 18 February 2019

Breast Imaging Equipment Market - Global Industry Size, Analysis and Trends

19 February 2019, The global Breast Imaging Equipment Market is expected to grow at a fast pace over the forecast period (from 2012 to 2020). Growing occurrences of chronic ailments such as breast cancer are anticipated to drive product demand. Breast imaging equipment helps capture images of breast tissues to diagnose breast cancer. Rising awareness along with rapid innovations in technology is expected to boost the market in the forthcoming years.

With continuous technological developments, breast imaging devices are becoming increasingly digitalized and efficient in disease diagnosis. Factors such as high screening costs, stringent regulatory approval, low medical reimbursement procedures, and insufficient screening expertise are likely to hinder industry growth. Computer-aided diagnosis is expected to gain popularity in the worldwide market over the forecast period. Developing countries such as China, India, South Korea, and Brazil possess considerable market potential on account of high outsourcing rate and medical tourism.

Browse Details of Report @ https://www.hexaresearch.com/research-report/breast-imaging-equipment-industry

The global Breast Imaging Equipment Market is divided into products and regions. Products include breast MRI, nuclear imaging, mammography, tomosynthesis, bioelectric images, breast ultrasound, and scintimammography. Mammography is an extensively used method for detecting breast cancer. It is also considered the standard technique for diagnosis and screening. It uses very low doses of X-ray to capture 2D images of human breasts and reduces the adverse effects after screening. The second most preferred method is breast ultrasound; used for breast cancer testing. This segment may grow at a healthy rate over the forecast period due to its effectiveness in identifying breast tumors & cancers by examining the stiffness in tissues. Breast MRI is also a very efficient method because it identifies probable anomalies by examining the densities of breast tissues.

Geographically the worldwide Breast Imaging Equipment Market is categorized into Europe, North America, Asia-Pacific (APAC), and RoW. North America was the leading regional market in 2013 in terms of revenue. This growth was attributed to the presence of high-end technology, high awareness levels about breast cancer diagnosis & treatment, and a rapidly growing female geriatric population.
Europe is the second largest regional industry. The region may exhibit substantial growth till 2020 due to an expanding target based population and high investments in sunk cost. APAC is also likely to grow rapidly on account of several healthcare reforms coupled with excellent government support. Some of the major companies in the global industry are Siemens Healthcare Corp.; Aurora Imaging Technologies Inc.; GE Healthcare Ltd.; and Dilon Technologies Inc. Most of these market players adopt various business strategies, such as acquisitions, joint venture, NDP, geographical expansions, etc. in order to thrive and prosper in the long run.

A new device has been developed for 3D breast imaging by expert researchers at Dilon Technologies (Department of Energy's Thomas Jefferson National Accelerator Facility) and at the University of Florida (Department of Biomedical Engineering). Utilized in conjunction with mammography, nuclear medicine-based imaging is presently being employed as a secondary screening tool. This is done in order to decrease the number of erroneous positive results in women that have dense breasts and are at a greater risk of developing breast cancer.

Related Category Reports @ https://www.hexaresearch.com/research-category/medical-imaging-industry

About Us:
Hexa Research is a market research and consulting organization, offering industry reports, custom research and consulting services to a host of key industries across the globe. We offer comprehensive business intelligence in the form of industry reports which help our clients obtain clarity about their business environment and enable them to undertake strategic growth initiatives.

Contact Us:
Ryan Shaw
Hexa Research
Felton Office Plaza
6265 Highway 9
Felton, California 95018
United States
Phone: +1-800-489-3075
Email: sales@hexaresearch.com
Website - https://www.hexaresearch.com/

Breast Cancer Market - Global Industry Size, Share, Analysis Report, 2025

19 February 2019, The global Breast Cancer Market is anticipated to witness a significant growth over the forecast period on account of growing target population base across the globe, rising prevalence of the disease, unhealthy lifestyle, exposure to radiations, and lack of physical exercises. Moreover, increasing efforts taken by major organizations across various regions to increase awareness levels is estimated to drive the market. Rising investments in R&D by various government and private organizations for development of effective drugs and treatments is also projected to play a key role in the market growth.

For instance, CytoDyn Inc., a biotech firm developing humanized CCR5 monoclonal antibodies for several therapeutic indications, received FDA approval for its Investigation New Drug (IND) submission and is allowed to start a phase 1b/2 trial for metastatic Triple-Negative Breast Cancer (TNBC). This disease subtype is one of the leading causes of cancer deaths across the globe and it accounts for around 10 % of the overall cases. The firm has identified several trial sites and aims to dose a few patients and expects to have initial readout during the first quarter of 2019. Changes in the number of Circulating Tumor Cells (CTCs) will be assessed every 21 days throughout the trial.

Browse Details of Report @ https://www.hexaresearch.com/research-report/breast-cancer-market

Breast cancer is detected during a screening test or after the patient notices a lump, which is the most common physical sign. According to the World Health organization (WHO), every year, about 200,000 new cases of breast cancer are diagnosed globally and this number is likely to increase in future. Some of the major types of breast cancer are ductal carcinoma in situ (DCIS), Invasive Ductal Carcinoma (IDC), and lobular carcinoma. Invasive ductal carcinoma hold a major share in the market owing to growing prevalence of IDC, government support, and initiatives undertaken to increase awareness among patients. Furthermore, unmet clinical needs in treatment of IDC has compelled manufacturers to conduct rigorous R&D activities. Chemotherapy, targeted, surgery and radiation, hormone, and biologic therapies are some of the most popular treatments for the disease.

North America has emerged as the prominent region in the market on account of changing lifestyle, growing prevalence of the disease, and presence of leading companies in U.S. Europe is likely to emerge highly lucrative over the coming years as a result of increased healthcare expenditure and technological developments. Countries, including Germany, France, and U.K., are some of the key revenue-generating economies in Europe.

Asia pacific is also projected to witness a considerable growth over the next few years owing to rapidly developing healthcare infrastructure and rising consumer disposable income. Moreover, ongoing awareness programs about breast cancer and available treatments by governments in the emerging countries, such as China and India are estimated to foster the growth.

Companies are adopting several business strategies, such as novel product development, technological advancements, and M&A in order to strengthen their foothold in the industry. For example, FDA recently approved the Investigational New Drug (IND) application for Athenex’s oral form of Eribulin. It is an anticancer drug promoted by Eisai Company under the brand name Halaven and can effectively treat metastatic breast cancer and liposarcoma. The company is allowed to initiate clinical trial program, which is expected to start in the first half of 2019. Other targeted therapies introduced to treat breast cancer include Perjeta (pertuzumab) and Kadcyla (T-DM1), which is a human antibody-drug conjugate. Leading companies operating in the global breast cancer market include Pfizer, Inc.; Novartis AG; Apthera, Inc.; BioNumerik Pharmaceuticals, Inc.; Eli Lilly and Company; and Oncothyreon, Inc.